Treatment FailureChagas DiseaseTreatment OutcomePractice Guidelines as TopicAnti-Bacterial AgentsUnited StatesHeart FailureAntimalarialsDrug CombinationsSulfadoxinePyrimethamineDrug ResistanceMalaria, FalciparumDrug Therapy, CombinationRetrospective StudiesChloroquineRecurrenceArtemisininsAmodiaquineFollow-Up StudiesProspective StudiesFluorenesProguanilKidney Failure, ChronicPlasmodium falciparumFailure to ThriveTime FactorsAtovaquoneDihydropteroate SynthaseSurvival AnalysisCefiximeDrug Resistance, ViralAnti-HIV AgentsPrognosisLiver Failure, AcuteDrug Administration ScheduleAntiprotozoal AgentsHIV InfectionsAntitubercular AgentsMicrobial Sensitivity TestsPenicillin G ProcaineParasitic Sensitivity TestsAmoxicillinAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesMetronidazoleSurvival RateDisease-Free SurvivalRisk FactorsLiver FailureDrug Resistance, BacterialGonorrheaMelarsoprolDrug MonitoringAzithromycinFluoxymesteroneViral LoadCombined Modality TherapyEthanolaminesKaplan-Meier EstimateMultiple Organ FailureParasitemiaPredictive Value of TestsAntiretroviral Therapy, Highly ActiveSalvage TherapyHodgkin DiseaseUgandaTrypanosoma brucei gambienseGenotypeCeftriaxoneDoxorubicinAnti-Infective AgentsDouble-Blind MethodMycoplasma genitaliumTetrahydrofolate DehydrogenaseAcute DiseaseVincristineAntimonyEquipment FailureCD4 Lymphocyte CountDisease ProgressionMutationCardiac Output, LowPharyngeal DiseasesPrednisoneSeverity of Illness IndexNeisseria gonorrhoeaeHeart Failure, SystolicAcute Kidney InjuryStaphylococcal InfectionsPatient ComplianceMefloquineVancomycinHIV-1Polymerase Chain ReactionAnti-Retroviral AgentsDrug Resistance, NeoplasmCyclophosphamideAntineoplastic AgentsChronic Disease